GlassScriptPhysician profile
Andrew M Appelbaum
NPI 1669565081
$15,791.04
in general payments reported to CMS, 2019-2025
54 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,613 · 2020: $2,181 · 2021: $2,284 · 2022: $2,629 · 2023: $1,848 · 2024: $1,786 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,128.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,461.54 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,312.25 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Novo Nordisk INC | $1,284.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,026.05 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $838.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $741.39 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $668.26 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $634.45 | 2019-2025 | Repatha, Krystexxa, Evenity |
| Pfizer INC. | $630.67 | 2019-2025 | |
| Gilead Sciences, INC. | $538.38 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $531.48 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $389.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $337.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.52 | 2019-2025 | Trintellix |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Appelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.